Hyderabad, India-based Aurobindo Pharma said that it will expand its facility at its East Windsor, New Jersey, campus to set up a manufacturing facility for injectable products. Aurobindo’s U.S., business chief, Bob Cunard, said in an earnings briefing that “the company has the bandwidth to add manufacturing in the United States.”
At its current New Jersey facility, the company makes non-penicillin and non-cephalosporin products. The bulk of its U.S. supply comes from India, where it has six plants. It gets more than half its total revenue from selling drugs for HIV/AIDS, asthma, and schizophrenia, among others, to the U.S.
India’s drug industry is worth about $15 billion and it supplies roughly 30 percent of the medicines sold in the U.S. reports Business Line.
